Fred Hutchinson

What Fred Hutchinson does

Fred Hutchinson Cancer Center is an independent nonprofit 501(c)(3) cancer research and treatment institution founded in 1975 in Seattle, Washington, and operating across clinical locations in Seattle, Kirkland, Bellevue, and Issaquah. It serves as UW Medicine's cancer program and is designated as an NCI Comprehensive Cancer Center, recognized by U.S. News & World Report as the top cancer hospital in the Pacific Northwest. The organization treats patients across more than 50 cancer types, runs over 750 active clinical trials, and employs 5,001–10,000 staff. Its clinical portfolio spans immunotherapy, blood and marrow transplantation (a modality Fred Hutch pioneered), medical oncology, radiation oncology, surgical oncology, proton therapy, CRS-HIPEC, radiology, and supportive care services. Patient-facing infrastructure includes the Epic MyChart portal and mobile app, telehealth services, and a regional mammogram van program.

The center's research operations span eight divisions covering basic sciences, clinical research, human biology, public health sciences, vaccine and infectious disease, and translational therapeutics, with active programs in CRISPR gene therapy, monoclonal antibody development (including EBV antibodies targeting gp350/gp42), liquid biopsy tools (PEARL for preeclampsia, Precede Bio Insight for solid tumors), and pandemic preparedness research. Strategic technology partnerships include AWS Amazon Bio Discovery for AI-driven antibody design and a memorandum of understanding with the Abu Dhabi Department of Health to leverage population-scale genomic data. Revenue is generated through patient care services reimbursed by Medicare, Medicaid, and private insurance; research grants from the NCI, American Cancer Society, and the Paul G. Allen estate's Fund for Science and Technology; and philanthropy through events such as Base 2 Space and Obliteride.

Name

Fred Hutchinson

Legal name

Fred Hutchinson Cancer Center

Website

https://fredhutch.org

Company type

Private

Founded year

1975

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Fred Hutchinson Cancer Center is an NCI-designated nonprofit cancer research and treatment institution in Seattle treating 50+ cancer types across 750+ clinical trials, serving as UW Medicine's cancer program and generating revenue through patient care, research grants, and philanthropy.

Ownership category

akta.pro rank

Product category

Cancer Treatment and Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Diagnostic Imaging Centers (621512)

SIC

Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Medical Oncology (HLAKAFAB), Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)

Keywords

• Cancer treatment services
• Clinical research
• Immunotherapy
• Blood marrow transplant
• Precision oncology

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Patient Care Services: Fred Hutch provides comprehensive cancer treatment services including chemotherapy, immunotherapy, radiation oncology, surgical oncology, proton therapy, blood and marrow transplant, and supportive care services. Revenue is generated through patient services, insurance reimbursements, and facility fees.
2. Research Grants and Funding: Fred Hutch receives significant funding through research grants from organizations including the National Cancer Institute, American Cancer Society, Fund for Science and Technology (Paul G. Allen estate), and various pharmaceutical and foundation sponsors.
3. Philanthropy and Donations: Fundraising activities including Base 2 Space stair climb event (raised record $1.16 million in 2025, bringing 10-year total to more than $5.8 million), Obliteride cycling event, direct donations, and planned giving programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Fred Hutchinson Cancer Center is an independent nonprofit organization that delivers comprehensive cancer treatment services—including immunotherapy, blood and marrow transplantation, medical, radiation and surgical oncology, proton therapy, and supportive care—while operating more than 750 active clinical trials and conducting laboratory research across eight scientific divisions. It functions as both an NCI-designated Comprehensive Cancer Center and the cancer program for UW Medicine, translating laboratory discoveries into clinical treatments.

Product overview

Fred Hutchinson Cancer Center is a comprehensive cancer research and clinical care institution offering a unified platform of treatment services, prevention programs, patient engagement tools, and research capabilities. The core clinical offerings include immunotherapy, blood and marrow transplant, medical oncology, radiation oncology, surgical oncology, proton therapy, and over 750 active clinical trials. Patient-facing digital services include the MyChart patient portal (web and mobile app) for accessing medical records, scheduling, and care team communication. Research operations span eight scientific divisions covering basic sciences through translational therapeutics. The institution does not operate a traditional software product business; rather, it provides clinical services, conducts scientific research, and collaborates on technology initiatives such as AI-driven drug discovery and genomics programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Immunotherapy for Cancer

Quantifiable outcome

• 27 of 28 stem cell transplant participants survived at least one year without severe rejection symptoms in pooled umbilical cord blood trial
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability14 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• UCSF, Mount Sinai, Institut PasteurcoreStrategic or Co-development Partner · 24 June 2026Fred Hutch researchers collaborated with UCSF, Mount Sinai, and Institut Pasteur on a study published in Cell Host & Microbe discovering that a single amino acid change in coronavirus protein Orf9b determines viral spillover potential from bats to humans.
• Abu Dhabi Department of Health and Abu Dhabi Public Health CentercoreStrategic or Co-development Partner · 14 May 2026Memorandum of understanding signed to collaborate on cancer research and personalized prevention. The partnership combines Abu Dhabi's clinical and genomic data infrastructure, AI capabilities, and governed data environments with Fred Hutch's globally recognized research expertise. Collaboration leverages Abu Dhabi's smart health system, liquid biopsy program, AI-driven early cancer detection, and the world's largest clinically integrated population genomics program with nearly one million sequenced genomes.
• Deverra TherapeuticscoreStrategic or Co-development Partner · 29 April 2026Researchers from Fred Hutchinson Cancer Center collaborated on clinical trials of dilanubicel, a pooled umbilical cord blood stem cell product developed by Deverra Therapeutics. The product combines blood stem cells from six to eight different cord blood units for improved transplant outcomes.
• Precede BiosciencescoreStrategic or Co-development Partner · 21 April 2026Fred Hutch collaborated with Precede Biosciences on studies presented at AACR 2026 demonstrating the assay's ability to predict therapeutic response and reveal resistance mechanisms in breast and prostate cancer using Precede Bio Insight liquid biopsy product.
• Amazon Web ServicescoreTechnology or Integration · 16 April 2026Fred Hutch Cancer Center is an early adopter of Amazon Bio Discovery, an AI-powered drug discovery platform. The platform provides access to biological foundation models and AI agents for evaluating antibody candidates. Fred Hutch joins Memorial Sloan Kettering, Bayer, Broad Institute, and Voyager Therapeutics as early adopters.
• Fight CRC and Pfizer (via NCCN Oncology Research Program)minorStrategic or Co-development Partner · 9 August 2023NCCN Oncology Research Program awarded grants to projects focused on optimizing biomarker-directed therapy in metastatic colorectal cancer, with collaborations involving Fight CRC and Pfizer. Projects aim to improve molecular profiling, reduce testing barriers, and increase access to personalized treatment.
• UW MedicinecoreStrategic or Co-development PartnerFred Hutch is an independent organization that also serves as the cancer program for UW Medicine. The partnership provides integrated cancer care with shared faculty, research collaborations, and coordinated patient care across both institutions.
• EvergreenHealth and OverlakecoreChannel Partner/ Reseller/ DistributorFred Hutch provides cancer care on the Eastside of King County in partnership with EvergreenHealth and Overlake, with locations in Kirkland, Bellevue, and Issaquah designed to meet patients where they are.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Memorial Sloan Kettering Cancer Center: NCI-designated Comprehensive Cancer Center in New York combining biomedical research with clinical oncology and a heavy immunotherapy focus. Comparable as a direct peer in scale, NCI designation, and translational research model; co-early adopter with Fred Hutch of the AWS Amazon Bio Discovery AI platform.
• MD Anderson Cancer Center: University of Texas–affiliated NCI Comprehensive Cancer Center, the largest U.S. cancer center by operating revenue. Comparable as the leading reference institution for combined research, clinical trials, and multidisciplinary cancer care, with overlapping services in immunotherapy, radiation oncology, and proton therapy.
• Dana-Farber Cancer Institute: Harvard Medical School–affiliated NCI Comprehensive Cancer Center with a parallel model of research-driven clinical care and a heavy emphasis on immunotherapy and precision oncology. Directly comparable in mission and translational research depth; collaborated with Fred Hutch on the Precede Bio Insight AACR 2026 launch.
• Stanford Cancer Institute: Stanford Medicine's NCI-designated Comprehensive Cancer Center combining translational research, clinical trials, and precision oncology. Comparable as a West Coast academic peer with similar technology-forward research orientation and clinical trial volume.
• UCSF Helen Diller Family Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center at UCSF with a parallel model combining research across immunology, genomics, and population science with multidisciplinary clinical care. Directly comparable as a Northern California academic cancer center with overlapping research and clinical focus.
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: Johns Hopkins–affiliated NCI Comprehensive Cancer Center operating a research-clinical integration model similar to Fred Hutch's, with strong programs in immunotherapy, BMT, and translational science. Comparable in mission and academic orientation.
• City of Hope Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center in Southern California with deep expertise in BMT, immunotherapy, and translational research. Comparable as a research-intensive academic cancer center with overlapping hematologic oncology and cellular therapy programs.
• Roswell Park Comprehensive Cancer Center: The first NCI-designated Comprehensive Cancer Center in the U.S., operating a combined research and clinical model focused on immunotherapy, BMT, and population sciences. Comparable as a longstanding nonprofit cancer center with parallel mission and grant-funding profile.

Broad incumbents

• Mayo Clinic Comprehensive Cancer Center: Massive multi-specialty academic medical system with an NCI Comprehensive Cancer Center program embedded within a much broader clinical enterprise. Comparable in cancer research and clinical depth but materially larger and more diversified than Fred Hutch's cancer-only focus.

Regional players

• Seattle Children's Hospital: Pediatric academic health system in Seattle sharing clinical workforce dynamics and joint unionization activity with Fred Hutch and UW Medicine. Comparable as a regional peer where Seattle-area clinical labor and partnership dynamics intersect.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/fredhutch
• Facebookfacebook.com/HutchinsonCenter
• LinkedInlinkedin.com/company/fred-hutchinson-cancer-research-center

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fred Hutchinson